Specific Inhibition of the Classical Complement Pathway by C1q-Binding Peptides

• Published in: The Journal of immunology (1950) 2001-12, Vol.167 (12), p.7052-7059
• Main Authors: Roos, Anja, Nauta, Alma J, Broers, Daniel, Faber-Krol, Maria C, Trouw, Leendert A, Drijfhout, Jan Wouter, Daha, Mohamed R
• Format: Article
• Language: English
• Subjects: Amino Acid Sequence; Animals; Binding, Competitive; Cell Line; Complement C1q - antagonists & inhibitors; Complement C1q - metabolism; complement component C1q; complement component C3; complement component C4; Complement Hemolytic Activity Assay; complement inhibitors; Complement Pathway, Classical - drug effects; Dose-Response Relationship, Drug; Graft Rejection - drug therapy; Humans; Immune Complex Diseases - drug therapy; Immunoglobulin G - metabolism; Oligopeptides - chemistry; Oligopeptides - metabolism; Oligopeptides - pharmacology; Peptides - metabolism; Peptides - pharmacology; Primates; Rats; Species Specificity; Swine; Transplantation, Heterologous
• ISSN: 0022-1767; 1550-6606
• DOI: 10.4049/jimmunol.167.12.7052

Undesired activation of the complement system is a major pathogenic factor contributing to various immune complex diseases and conditions such as hyperacute xenograft rejection. We aim for prevention of complement-mediated damage by specific inhibition of the classical complement pathway, thus not affecting the antimicrobial functions of the complement system via the alternative pathway and the lectin pathway. Therefore, 42 peptides previously selected from phage-displayed peptide libraries on basis of C1q binding were synthesized and examined for their ability to inhibit the function of C1q. From seven peptides that showed inhibition of C1q hemolytic activity but no inhibition of the alternative complement pathway, one peptide (2J) was selected and further studied. Peptide 2J inhibited the hemolytic activity of C1q from human, chimpanzee, rhesus monkey, rat, and mouse origin, all with a similar dose-response relationship (IC(50) 2-6 microM). Binding of C1q to peptide 2J involved the globular head domain of C1q. In line with this interaction, peptide 2J dose-dependently inhibited the binding of C1q to IgG and blocked activation of C4 and C3 and formation of C5b-9 induced via classical pathway activation, as assessed by ELISA. Furthermore, the peptide strongly inhibited the deposition of C4 and C3 on pig cells following their exposure to human xenoreactive Abs and complement. We conclude that peptide 2J is a promising reagent for the development of a therapeutic inhibitor of the earliest step of the classical complement pathway, i.e., the binding of C1q to its target.